A case report described confusion and agitation after zopiclone, followed by rapid improvement after flumazenil. The authors treated the drug relationship as suspected, with competing medical explanations.
The reported chronology
An 81-year-old woman with severe chronic obstructive pulmonary disease and pneumonia was receiving intensive care and noninvasive ventilation. After an unsuccessful attempt to address sleep difficulties with dexmedetomidine, she received zopiclone and slept for approximately four hours.
She then became agitated, confused, and restless. Following flumazenil, the behavioral symptoms resolved within minutes and did not recur during hospitalization. She did not recall the episode.
Why the inference remains limited
Severe illness and the intensive-care environment can themselves produce delirium. The authors did not demonstrate a causal relationship and did not perform toxicological screening. Prior zopiclone exposure was uncertain. A response to an antagonist strengthened the clinical suspicion but did not eliminate every alternative explanation.
Zopiclone is a Z-drug, not a conventional benzodiazepine, despite its relationship to the benzodiazepine-sensitive GABA-A receptor complex. The distinction matters when describing the case.
Use of a single observation
The report supports considering medication timing when unexpected behavior develops. It does not estimate reaction frequency, establish a concentration threshold, or justify a universal reversal strategy. The paper itself cautioned about flumazenil in people dependent on benzodiazepines or receiving them for seizure control.
Source
Original analysis of the supplied paper: Reversal of a Suspected Paradoxical Reaction to Zopiclone with Flumazenil. Paper identifier: PMC5031812.
Leave a Reply